Suchergebnisse

The first step of management functions is planning. It is the starting point of a process. It asks what needs to be done and how it should be done in order to achieve business objectives. The planning phase also defines the goals, policies, programs and procedures for program implementation for the company or individual departments. Planning is also considered a primary function. This phase is designed to avoid errors as far as possible, as they can affect all other management functions.

This comprehensive textbook is tailored for Pharma MBA students, part-time MBA students specializing in Pharma, and SCM enthusiasts. With 36 insightful chapters divided into 5 parts, this book delves into the core principles, strategies, and emerging trends essential for navigating the dynamic landscape of pharmaceutical supply chains.

1. Managing pharmaceutical projects strategically -- 2. Linking pharmaceutical projects with business strategy -- 3. Defining pharmaceutical projects -- 4. Developing pharmaceutical project strategy plans -- 5. Evaluation pharmaceutical projects -- 6. Pharmaceutical project mobilisation, control and learning -- 7. Influencing people and behaviour -- 8. Project management checklists and cost-management project case study -- 9. Conclusion.

Encompassing the full spectrum of project management's role and responsibility encountered in the pharmaceutical industry, Pharmaceutical Project Management outlines the key objectives, risks, and challenges of each stage of the pharmaceutical lifecycle, from discovery and preclinical phases through clinical development, manufacturing, registration, and launch.

A poster presentation regarding the simplification of procedures required for registration of medicines. Introduction: A medicine requires a Marketing Authorisation (MA) before it could be made available on the EU market (Directive 2001/83/EC). This registration process ensures the safety, quality and efficacy of medicines on the market. The requirements to obtain a MA are complex and may adversely influence accessibility to medicines. The problem of accessibility to medicines is of particular interest to small countries such as Malta. The availability of high quality medicines that are not very expensive promotes confidence in health systems, health care professionals and the pharmaceutical industry. The research question of this study was: Can registration of medicines in small EU countries such as Malta be simplified? Aims:  To review the processes by which medicines are registered in the EU, with particular interest to small countries  To analyse the strengths and weaknesses of registration processes and identify challenges in the registration process in Malta  To compile a guide intended to simplify the process for the registration of medicines in Malta and in small EU countries ; N/A

"The Pharmaceutical Industry: Is Pharmaceutical Research Safe and Unbiased?; Are Prescription Drugs Appropriately Regulated?; Are Pharmaceutical Marketing Practices Ethical?; Is the Cost of Prescription Drugs in America Appropriate?"--Provided by publisher

Governments across the world are looking for ways to balance a number of competing policy goals including economic growth; industrial development; attraction of foreign direct investment; advances in education, science and technology; overall budgetary control; and complex and evolving healthcare needs. ; peer-reviewed

Reproduced from a Position Paper published by the European Federation of Pharmaceutical Industries and Associations, February 2014 ; The research-based pharmaceutical industry considers that price differentiation between EU Member States could greatly improve affordable patient access to innovative medicines in those markets where there is a significant access problem. Adapting prices of pharmaceuticals to reflect the ability to pay in different geographical or even socio-economic segments can offer a win-win situation in terms of generating dynamic efficiencies that contribute to both the sustainability of healthcare systems and the pace of innovation. Yet today's pricing and reimbursement practices have the effect of discouraging price differentiation. Member State action and support from the European Union are required to create a framework to enable and encourage voluntary recourse to differentiated pricing. ; peer-reviewed

The revival of interest in workplace consultation in the UK reflects both a managerial drive for improved company performance and trade unions'aspirations that new legal rights may strengthen their role in the workplace. This article probes the links between managerial policy, union organization and activity and the wider product and labour market context through a case study of workplace consultation at a UK pharmaceutical plant. The research finds that both management and unions failed to gain from changes to the consultation process, largely as a result of the lack of strategic management, managerial fears about strengthening employee representation and weak trade unions.

The revival of interest in workplace consultation in the UK reflects both a managerial drive for improved company performance and trade unions' aspirations that new legal rights may strengthen their role in the workplace. This article probes the links between managerial policy, union organization and activity and the wider product and labour market context through a case study of workplace consultation at a UK pharmaceutical plant. The research finds that both management and unions failed to gain from changes to the consultation process, largely as a result of the lack of strategic management, managerial fears about strengthening employee representation and weak trade unions. (Economic and Industrial Democracy / FUB)